Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Bruce E StroberAndrew BlauveltRichard B WarrenKim A PappApril W ArmstrongKenneth B GordonAkimichi MoritaAndrew F AlexisMark LebwohlPeter FoleyRenata M KisaElizabeth ColstonTao WangSubhashis BanerjeeDiamant ThaçiPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Deucravacitinib was well-tolerated with acceptable safety over 52 weeks in patients with psoriasis.